is a research and development pharmaceutical company developing a portfolio of innovative products based on our proprietary, transdermal DermaSys® technology.
Our purpose is to enhance our patients and consumers’ quality of life through deep science to enable them to live their lives to the full.
Ken James speaks to Proactive Investor’s Andrew Scott following positive initial discussions with EU regulators after an extensive internal evaluation of the clinical data from the Phase 3 study (“FM57”).
Futura Medical is developing a portfolio of innovative products for two large markets, sexual health and pain. Our late stage pipeline of products is based on our proprietary, transdermal DernaSys® technology designed to deliver clinically proven effective pharmaceutical treatments via the skin.
Lead product MED3000, is the only easy to use topical treatment for erectile dysfunction.
MED3000 which utilises our proprietary DermaSys® technology is a topical gel developed specifically for the treatment of erectile dysfunction (ED).
TPR100 is a topical non-steroidal anti-inflammatory for the pain and inflammation associated with sprains, strains and bruises and soft tissue rheumatism.
Our investor centre includes all key investor information such as corporate documents, share price chart and the information required pursuant to AIM Rule 26.
Futura has a proven track record in delivery and completion of Research & Development projects up to value inflection points at which they are suitable for commercialisation partners.
Current therapeutic areas are sexual health and pain relief. Development and commercialisation strategies are designed to maximise product differentiation and value creation whilst seeking to minimise risk.
